Recent Company News

• 07:09 PM ET Dec 17, 2025
  

  Innovent Biologics notes results of two Phase 3 clinical studies of mazdutide in Chinese adults with type 2 diabetes published back-to-back in Nature (HK$80.75, 0.00)

• 07:11 PM ET Dec 11, 2025
  

  Innovent Biologics' phase 1B clinical study of mazdutide injection in Chinese adolescents with obesity meets primary endpoint (HK$83.65, 0.00)

• 07:31 PM ET Dec 09, 2025
  

  Innovent Biologics doses first participant in phase 1 clinical trial of IBI3011 (HK$84.40, 0.00)

• 08:59 AM ET Dec 09, 2025
  

  Ascentage Pharma presents four-year follow-up data Phase II study of Olverembatinib, reaffirming differentiated long-term efficacy and safety in TKI-Resistant/Intolerant CML-CP - 6-K (HK$59.30, 0.00)

• 10:10 PM ET Dec 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 07:49 PM ET Dec 08, 2025
  

  Ascentage Pharma presents latest data on Olverembatinib in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP) at ASH meeting (HK$62.15, 0.00)

• 07:03 PM ET Dec 08, 2025
  

  Innovent Biologics announces PECONDLE (Picankibart injection) Phase 3 study (CLEAR-2) meets endpoints (HK$85.60, 0.00)

• 10:16 PM ET Dec 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 08:33 PM ET Dec 07, 2025
  

  StreetAccount China Healthcare Sector Update: China reveals 2025 National Reimbursement Drug List, 114 newly added, 19 made commercial insurance list